Effects of erythropoietin on mobilisation of haemopoietic progenitor cells.
AffiliationDepartment of Medical Oncology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractPeripheral blood progenitor cell (PBPC) mobilising regimens that do not include cytotoxic drugs are needed if PBPC are to be used for allogeneic transplantation. We have studied the effects of erythropoietin on bone marrow and circulating haemopoietic progenitors. Eleven patients with untreated lymphoma received epoetin-alpha 300 or 450 iu/kg subcutaneously (sc) thrice weekly for 2 weeks. Their bone marrows and peripheral bloods were normal at entry. There were no differences between dose levels. Peripheral blood colony-forming cell (CFC) numbers increased fivefold over baseline (p = 0.003) including a sevenfold increase in GM-CFC (p = 0.003). CD34-positive cell numbers increased 4.6-fold (P < 0.01). Maximal CFC release was seen at days 5-8. No consistent change in megakaryocyte numbers was seen. The increase in numbers of cells capable of long-term haemopoiesis was not significant. The ratio of myeloid:erythroid cells in bone marrow reduced from 2.7 to 0.86 after erythropoietin treatment (p = 0.047). In bone marrow the only significant rise in CFCs was in erythroid progenitors. Erythropoietin alone resulted in a modest increase in PBPC that is unlikely to be useful for transplantation. The effects of erythropoietin in combination with other cytokines or with cytotoxic drugs remain to be explored.
CitationEffects of erythropoietin on mobilisation of haemopoietic progenitor cells. 1994, 14 (1):125-30 Bone Marrow Transplant.
JournalBone Marrow Transplantation
- Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
- Authors: Lemoli RM, Fortuna A, Fogli M, Gherlinzoni F, Rosti G, Catani L, Gozzetti A, Miggiano MC, Tura S
- Issue date: 1995 Dec
- Plastic-adherent progenitor cells in mobilized peripheral blood progenitor cell collections.
- Authors: Scott MA, Apperley JF, Jestice HK, Bloxham DM, Marcus RE, Gordon MY
- Issue date: 1995 Dec 15
- Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
- Authors: Lopez M, Lemoine FM, Firat H, Fouillard L, Laporte JP, Lesage S, Isnard F, Stachowiak J, Ferrer-Le Coeur F, Morel P, Najman A, Douay L, Gorin NC
- Issue date: 1997 Oct 1
- Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane.
- Authors: Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montaño J, Chang H, Rozmus J, Russell JA, Edwards DR, Turner AR
- Issue date: 1999 May 15
- Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
- Authors: Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, Broun ER, Bayer RA, Wyres M, Hill J, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, Gabrilove J
- Issue date: 1997 May 1